Immupharma Plc (IMM.GB) Quote

Ya! Don't hold your breath 

What happened with orgn? Weren't you talking about that before? Why do you still believe in this stuff? Like real said you need to just be a gentleman and admit you're wrong

FNMA/FMCC
Shhhhhhhhh

I would also love to see all ex-biotech executives do the same including those who managed to completely mislead themselves and others regarding the paediatric Anavex Rett trial outcome.

Since when do they allow reporters into a terrorist’s home the day after an attack?

Wouldn’t that taint the evidence?

Or inspire copycats?

This feels weird
https://x.com/DC_Draino/status/1875027420027506703

I saw 8 grand get slapped at .16 with a 100% spread. Something is coming. This happened before and it went to $3+

Part 4 of 4. Another week passes. 01/03/2025.

Potentially on the positive side, like the positive theories, LQMT can break a dime in the next quarter. Based on existing potential and a new contract. More Examples of this theory can come from Amorphology Inc., and the ring company. But

NVDA (NVIDIA) Weekly Analysis
By: TrendSpider | January 3, 2025

• Following last week’s bull flag breakout, NVDA is set to enter a historically strong three-week stretch, including its best-performing week of the year, averaging a return of 7.37%. After lagging since the U

Part 3 of 4. Another week passes. 01/03/2025.

Every outside long term is in the red regardless of their opinions if that helps you. Always do your own due diligence.

Increasing manufacturing capacity in China only increases potential for China to increase their own sha

Draino thinks Massie is a never Trumper. I always thought he was super fiscally conservative. We will see.

Good job Massie

Per the usual, you engaged in a lot of self-serving theatrics, nobody agreed with you, and you changed nothing
https://x.com/DC_Draino/statu

Gonna assume you mean for our drug. In the small phase 2a, there was. For the 2b/3, there is a chart only relatively recently provided by the company that shows potential positive ADL trend for dosed vs placebo, though not stat-sig.

You'll have to define "improvement". Note that any c

The drug effect you're trying to prove in the context of this thread is the abandoned and immaterial ADL endpoint, which would clearly benefit from more time in a trial. However, there is no point to that endpoint, whose time is at an end, if you get my point.

$ILLR Triller is a great way to profit from the demise of TikTok in the US!

https://investorshub.advfn.com/uimage/uploads/2024/12/1/wqnywtik-cban-coming.gif

So if the EMA approves the MAA is the study still insufficient?

QQQ (Invesco QQQ Trust) Weekly Analysis
By: TrendSpider | January 3, 2025

• The QQQ ETF delivered the highest percentage returns in 2024, climbing $109.78 per share to close the year at $511.23 (+27.05%). Unlike the SPY, which struggled in Q4, the tech-heavy index regained

Triller is a great way to profit from the demise of TikTok in the US!
$ILLR

https://investorshub.advfn.com/uimage/uploads/2024/12/1/wqnywtik-cban-coming.gif

And no dilution since Melvin retired shares!!! Brilliant 

Part 1of 4. Another week passes 01/03/2025.
Another week and another year passes and LQMT’s share price is down 3.45% from 0.042 cents to 0.04055 cents for the week and down 33% for the year 2024, on extremely weak trading volumes and little interest. The same when LQMT moves up or down. And

An AVXL investment at $13.30 offers an extremely favorable risk/reward ratio given the current odds of EMA approval between 60% and 90% according to ChatGPT.
As may be recalled, Biogen, upon the disputed approval for their Alzheimer's drug, gained $16 Billion or about 40% in price.
A

Speaker Johnson was just re-elected for a 2nd term with the gavel

Was he MAGA’s top choice? Not even close

Is he better than McCarthy? Yes

Can he be pressured towards the MAGA agenda? Absolutely

We now have Trump in the White House, Elon on

SPY (SPDR S&P 500) Weekly Analysis
By: TrendSpider | January 3, 2025

• The SPY ETF emerged as the top dollar gainer in 2024, adding an impressive $113.41 per share to close the year at $586.02 (+23.99%). However, Q4 delivered the most modest gains of the year, with the ind

Haha, working you two like a puppet, I gotta go wash up, finger tips to the elbow. Enjoy your Saturday, gotta catch a flight. But you made my wait at the gate so much fun today.

They have cut their deals. Did your comprehend the last PR?
The last PR was a deal where York agreed to sell the shares into the market for them. It is exactly what they have been doing for years, but now they paid somebody to run it for them.

They will still be limited by the